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Abstract
Liver specific contrast media (LSCM) can be subdivided according to different modalities of hepatic distribution:
exclusive distribution to the hepatocellular compartment can be obtained using CM which accumulate within the
hepatocytes after slow infusion; other CM demonstrate combined perfusion and hepatocyte-selective properties, with
an initial distribution to the vascular-interstitial compartment (in an analogous manner to that of the conventional
extracellular CM), thereafter, a fraction of the injected dose is taken up into the hepatocytes causing an increase in the
signal intensity of the hepatic tissue. The use of the superparamagnetic effect of iron oxide particles is based on
distribution in the reticuloendothelial system (RES), usually well represented in the normal parenchyma as well as in
benign hepatocellular lesions, and absent in most malignant lesions. It is necessary to have an in-depth knowledge
of either the biological and histological characteristics of focal liver lesions (FLL) or the enhancement mechanism
of LSCM to gain significant accuracy in the differential diagnosis of FLL. Dynamic contrast-enhanced MRI is an
important tool in the identification and characterization of FLL. With LSCM it is possible to differentiate benign from
malignant lesions and hepatocellular lesions from non hepatocellular lesions with high accuracy. To understand the
contrast behaviour after injection of LSCM it is necessary to correlate the contrast enhancement with both
the biological and histological findings of FLL.
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Introduction
MRI is an established imaging method for the evaluation
of focal liver lesions; in order to adequately characterize
focal hepatic lesions on magnetic resonance imaging
(MRI), it is necessary to utilize contrast media (CM)
which are able to modify the signal intensity of either the
lesion or normal liver parenchyma and thus contribute
towards the characterization of the lesion[1!4].
The sensitivity of MR to the variations of signal
intensity induced by CM has led to the development of
several different types of liver specific contrast media
(LSCM), which utilize the paramagnetic properties of
gadolinium or manganese or the superparamagnetic
properties of iron. Non-specific gadolinium chelates
such as gadolinium-diethylenetriamine penta-acetic acid
(Gd-DTPA) (Magnevist, Schering AG, Berlin, Germany)
and Gd-DTPA-bismethylamide (BMA) (Amersham
Health, Oslo, Norway)[5] which distribute in the extra-
cellular fluid (ECF) space are currently the most widely
employed CM. These CM are most effective during the
dynamic phase of contrast enhancement when differen-
tial blood flow between tumour and normal liver
parenchyma leads to characteristic lesion enhancement
patterns[2,3]. Unfortunately, dynamic phase imaging
alone can, at times, prove unsatisfactory for the accurate
diagnosis of hepatic lesions[6].
Classification of LSCM
The development of CM with liver-specific properties has
increased the accuracy of MR for the identification and
characterization of focal liver lesions[7!10]. The various
CM can be distinguished on the basis of their distribution
after intravenous injection.
Exclusive distribution to the hepatocellular compart-
ment can be obtained using CM which ! when injected
by means of slow infusion ! accumulate within the
hepatocytes and cause an increase in the proton
relaxation rate. In mangafodipir trisodium (Mn-DPDP,
Teslascan, Nycomed, Oslo, Norway), the manganese ion
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is chelated with four molecules of meglumine. The
molecule is isotonic with blood and has a low viscosity.
It is infused slowly (2!3ml/min over a 10!20min
period) at a concentration of 10mmol/ml, and at a dose
of 0.5ml/kg. After administration, the Mn2þ ion
contained in the molecule is gradually released into the
blood from the DPDP chelate, and is substituted by zinc.
The latter has an affinity for the chelant that is hundreds
of times greater than that of Mn2þ. The free Mn2þ is
then available for uptake into parenchymal cells,
particularly those of the liver, pancreas, kidneys and
adrenals in which metabolism of this metal takes place.
Maximum tissue enhancement is observed at the end of
the infusion after approximately 20min and lasts for
around 4 h[11]. Tumours of non-hepatocytic origin show
little or no tumour enhancement resulting in increased
lesion conspicuity. Several studies have shown improved
lesion detection on images obtained after infusion of
mangafodipir trisodium compared with pre-contrast
images[12,13]. In a multicenter study, mangafodipir
trisodium enhanced MRI in 77 patients with histologi-
cally confirmed lesions and had a sensitivity and
specificity in differentiating lesions of 91% and 67%
(malignant vs benign lesions) and 91% and 85%
(hepatocellular vs non-hepatocellular lesions), respec-
tively[14]. However, uptake of mangafodipir trisodium by
both benign and malignant hepatic neoplasms limits the
accurate differentiation between benign and malignant
tumours of hepatocellular nature[15!17] and represents a
major shortcoming of this agent. The significant biliary
excretion may aid in the assessment of the patency of
biliary-enteric anastomoses[18] and can be of value in the
detection of complications of biliary surgery.
Other CM demonstrate combined perfusion and
hepatocyte-selective properties. Such compounds distri-
bute initially to the vascular-interstitial compartment in
an analogous manner to that of conventional, extra-
cellular CM. Thereafter, a fraction of the injected dose is
taken up into the hepatocytes causing an increase in the
signal intensity of the hepatic tissue. Agents of this type
include gadobenate dimeglumine (Gd-BOPTA,
Multihance, Bracco SpA, Milan, Italy), and gadolinium-
ethoxybenzyl-DTPA (Gd-EOB-DTPA, Primovist, Bayer
Schering Pharma SpA, Berlin, Germany).
Gadobenate dimeglumine
Gadobenate dimeglumine is a chelate of the paramag-
netic gadolinium ion, salified with two molecules
of meglumine. Gd-BOPTA is a second generation
gadolinium chelate which combines the properties of a
conventional extracellular gadolinium agent with those of
an agent targeted specifically for the liver[19]. Gd-BOPTA
has an elimination profile that sees roughly 96% of the
injected dose excreted renally via glomerular filtration;
the remaining 2!4% taken up by functioning hepatocytes
is eliminated in the bile via the hepatobiliary pathway[20],
leading to a marked and long-lasting enhancement of the
signal intensity of normal liver parenchyma beginning
40min after Gd-BOPTA administration[21]. Gd-BOPTA
behaves in an analogous way to conventional gadolinium
agents during the dynamic phase of contrast enhance-
ment[22], while in the delayed phase it not only improves
the impact of MRI for the detection of focal liver
lesions[1,23], but may also contribute to the improved
characterization of detected lesions, particularly lesions
demonstrating atypical enhancement on dynamic ima-
ging[24,25]. For example, accurate characterization of
focal nodular hyperplasia (FNH) is not always possible
since atypical features can confound the interpretation.
The Gd-BOPTA enhancement dynamics of FNH in the
early phases parallel those seen with conventional
extracellular agents. During the hepatobiliary phase
(1!3 h after injection) on T1-weigted images substantial
enhancement is noted within the parenchyma of FNH
and the lesion appears iso- or hyperintense to the
surrounding liver[25], whereas the central scar, which is
the principal site of the biliary metaplasia, appears
consistently hypointense. On the contrary, hepatic
adenoma, which frequently affects women with a history
of oral contraceptive use and needs to be differentiated
by FNH, on delayed phase images after injection of
Gd-BOPTA shows little evidence of uptake and appears
hypointense[26,27].
Gadolinium ethoxybenzyldiethylenetriamine-
pentaacetic acid
Gadolinium ethoxybenzyldiethylenetriaminepentaacetic
acid exploits the ‘carrier’ used by hepatocytes for the
uptake of bilirubin[28]. In an analogous manner to that of
Gd-BOPTA, this CM distributes initially to the vascular-
interstitial compartment after injection. With Gd-EOB-
DTPA about 50% of the injected dose is taken up and
eliminated via the hepatobiliary pathway. The maximum
increase in liver parenchyma signal intensity is observed
about 20min after injection and lasts for approximately
2 h[29]. During the perfusion phase the dynamic
enhancement patterns seen after injection of Gd-EOB-
DTPA are similar to those seen with Gd-DTPA, while
during the hepatobiliary phase Gd-EOB-DTPA-enhanced
images have been shown to yield a statistically significant
improvement in the detection rate of FLL compared
with unenhanced and Gd-DTPA-enhanced images[10],
with a modality of enhancement of the different FLL
which is similar to that observed with Gd-BOPTA.
Superparamagnetic iron oxide
The use of the superparamagnetic effect of iron oxide
particles is based on distribution in the reticuloendothe-
lial system (RES). The presence of superparamagnetic
iron oxide locally augments the externally applied
magnetic field, producing magnetic field heterogeneity
which in turn, promotes dephasing, and results in signal
loss from enhanced T2 relaxation. Superparamagnetic
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iron oxide (SPIO) particles are cleared from the blood
by phagocytosis accomplished by RES so that uptake is
observed in the normal liver, spleen, bone marrow, and
lymph nodes[30]. Inflammation, scarring, regeneration
and shunting in cirrhotic liver reduces hepatic uptake of
SPIO, shifts distribution to the spleen, and produces
signal heterogeneity. Most focal liver lesions, mainly
malignant ones, lack Kupffer’s cells or the capacity to
take up particles. After SPIO injection, the darkening of
normal liver parenchyma which surrounds focal liver
lesions increases the contrast/noise ratio (CNR) of these
lesions, usually slightly hyperintense on precontrast
T2-weighted images, which appear more hyperintense
at T2-weighted images.
Ferumoxides
Ferumoxides (Feridex IV, Berlex Laboratories Wayne,
NY; and Endorem, Guerbet, Aulnay Sous Bois, France)
were developed by Advanced Magnetics (Cambridge,
MA) and referred to as AMI-25. Ferumoxides is an
SPIO colloid with low molecular weight dextrane, with a
particle size of 50!180 nm, according to the analytical
system utilized (electron microscopy or photocorrelation
spectroscopy)[31].
At about 8min following an intravenous injection, iron
oxide particles are taken up by the reticululoendothelial
cells in the liver (Kupffer cells) and in the spleen with an
approximate uptake of 80% and 6!10%, respectively[30].
Maximum signal loss is obtained after 1 h with an
imaging window ranging from 30min to 6 h after the
injection[32,33]. The recommended dose is 15mmol/kg.
To reduce the incidence of some side effects such as
hypotension, ferumoxides is prepared as a dilution
in 100ml of 5% dextrose and administered as a drip
infusion over about 30min. Hypotension and lumbar
pain represent the most frequent symptoms associated
with SPIO administration with an incidence ranging from
2 to 10%[31].
The clinical efficacy of Ferumoxides for detection of
focal liver lesions on T2-weighted images has been
investigated in several trials. In a multicenter trial,
ferumoxides-enhanced T2-weighted images revealed addi-
tional lesions not seen on unenhanced images in 27% of
cases and additional lesions not seen by conventional
(non-spiral) computed tomography (CT) scans in 40%;
the additional information would have changed therapy
in 59% of cases[33]. A comparison with spiral CT has
demonstrated a better sensitivity of SPIO-enhanced
MR images, but at the expense of reduced specificity
with a higher number of false positive cases[34]. Other
studies have compared the efficacy of SPIO-enhanced
T2-weighted MR images to computed tomography during
arterial portography (CTAP), and these have shown a
higher sensitivity and specificity of MR images, especially
with T2*-weighted breath-hold gradient echo (GRE)
images. A study demonstrated a better sensitivity of
CTAP, when performed with spiral CT[35].
SH U 555 A (Ferucarbotran)
SH U 555A (Ferucarbotran) is the code name of an
SPIO contrast agent registered as Resovist" (Schering
AG, Berlin, Germany) and commercially available since
2001. The active particles are carboxydextrane-coated
super-paramagnetic iron oxide, with a hydrodynamic
diameter ranging between 45 and 60 nm. The differing
particle sizes determine the velocity of their uptake
by cells of the RES, specially the Kupffer cells in
the liver, as well as the relaxivity-related effects. It can be
administered as a fast bolus. SH U 555A has a strong
effect on the shortening of both T1 and T2 relaxation
time. Due to the high R2 relaxivity it is particularly
suited to T2- and T2*-weighted imaging. Furthermore,
SH U 555A enables T1-weighted imaging with a
tenth of the standard dose of extracellular contrast
agents (Gd-DTPA) ensuring a valuable although less
pronounced T1 effect. Fast bolus injection of SH U
555A makes it possible to observe the early perfusion
characteristics of the liver using T1- or T2*-weighted
sequences. The accumulation phase imaging (RES
phase) can be performed as early as 10min post-injection
utilising T1-, T2- and T2*-weighted sequences. The T2-
and T2*-weighted accumulation phase imaging improves
the visualisation, delineation and conspicuity of the
lesions and hence improves detection[36]. However, the
combined approach of non-enhanced and SPIO-
enhanced T2-weighted MR images together resulted
in a significantly higher sensitivity as well as in
significantly more accurate differentiation of benign
from malignant lesions as compared with results from
spiral CT images, non-enhanced T2-weighted MR images
or SPIO-enhanced T2-weighted images alone[37].
Conclusions
The utilization of ECF gadolinium-based contrast agents
with dynamic acquisition is the predominant means of
contrast-enhanced liver MRI. However, increased utiliza-
tion of targeted CM can improve the sensitivity and
specificity of the MR study in the identification and
characterization of focal liver lesions. Expertise with all
these agents will further reduce the need for tissue
sampling and allow a better non-invasive means to triage
patients with hepatic malignancies.
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